Adaptive Biotechnologies (ADPT) Gross Margin (2018 - 2026)
Adaptive Biotechnologies (ADPT) posted Gross Margin of 73.6% for Q1 2026, down 1.3% sequentially from 74.58% in Q4 2025, and up 598.0% YoY from 10.54% in Q1 2025.
Adaptive Biotechnologies (ADPT) Gross Margin (2018 - 2026) Analysis & Trends
Adaptive Biotechnologies has reported Gross Margin for 9 years, with the latest figure at 73.6% in Q1 2026.
- Quarterly Gross Margin rose 598.0% year-over-year to 73.6% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 75.26% (up 1272.0% YoY) and the FY2025 annual result came in at 74.24%, up 1451.0% from the prior year.
- Gross Margin fell to 73.6% in Q1 2026 per ADPT's latest filing, from 74.58% in the prior quarter.
- Over five years, Gross Margin peaked at 80.68% in Q3 2025 and troughed at 132.6% in Q2 2023.
- A 5-year average of 53.08% and a median of 65.84% in 2022 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2023 and 2024: Gross Margin plunged 20232 bps in 2023, then soared 18787 bps in 2024.
- Over 5 years, Gross Margin stood at 69.95% in 2022, then decreased by 18 bps to 57.16% in 2023, then grew by 8 bps to 61.98% in 2024, then increased by 20 bps to 74.58% in 2025, then slipped by 1 bps to 73.6% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 73.6%, 74.58%, and 80.68% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 69.57% |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 57.64% |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 64.04% |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 53.95% |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 32.85% |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | 99.91% |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 66.44% |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 63.29% |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 33.75% |
| 10 | Adaptive Biotechnologies | 3.80 Bn | 3.58 Bn | 52.17 Mn | 73.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73.60% |
| Dec 31, 2025 | 74.58% |
| Sep 30, 2025 | 80.68% |
| Jun 30, 2025 | 69.43% |
| Mar 31, 2025 | 67.62% |
| Dec 31, 2024 | 61.98% |
| Sep 30, 2024 | 64.11% |
| Jun 30, 2024 | 55.27% |
| Mar 31, 2024 | 56.89% |
| Dec 31, 2023 | 57.16% |
| Sep 30, 2023 | 48.98% |
| Jun 30, 2023 | -132.60% |
| Mar 31, 2023 | 50.38% |
| Dec 31, 2022 | 69.95% |
| Sep 30, 2022 | 68.83% |
| Jun 30, 2022 | 69.72% |
| Mar 31, 2022 | 65.84% |
| Dec 31, 2021 | 62.15% |
| Sep 30, 2021 | 64.05% |
| Jun 30, 2021 | 72.04% |